References

  1. Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arc Dis Child. 2013; 98(11):908-914. PubMed | Google Scholar

  2. Manwani D, Frenette P S. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013; 122(24): 362-369. PubMed | Google Scholar

  3. Kanter J, Kruse-Jarres K. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood Reviews. 2013; 27: 279-287. PubMed | Google Scholar

  4. Milton J N, Gordeuk V R, Taylor VI J G, Gladwin M T, Steinberg M H, Sebastiani P. Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk. Circ Cardiovasc Genet. 2014; 7(2):110-115. PubMed | Google Scholar

  5. Hiromatsu Y, Satoh H, Amino N Hashimoto's. Thyroiditis: History and Future Outlook. HORMONES. 2013; 12(1):12-18. PubMed | Google Scholar

  6. Steinberg M H, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012; 87(8):795-803. PubMed | Google Scholar

  7. Platt Orah S. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008; 358(13):1362-9. PubMed | Google Scholar

  8. Green N S, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2014; 75(0): 196-204. PubMed | Google Scholar

  9. Miller A C, Gladwin M T. Pulmonary complications of sickle cell Disease. Am J Respir Crit Care Med. 2012; 185 (11): 1154-1165. PubMed | Google Scholar

  10. Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV. Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost. 2012; 10(5): 760-6. PubMed | Google Scholar

  11. Krishnamoorthy P, Alyaarubi S, Abish S, Gale M, Albuquerque P, Jabado N. Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. Pediatrics. 2006; 118(2):537-9. PubMed | Google Scholar